Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
drugs
9
×
fda
9
×
indiana blog main
9
×
indiana top stories
life sciences
national blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
cancer
eli lilly
teva pharmaceutical
astrazeneca
celgene
gene therapy
investing
merck
multiple myeloma
sarepta therapeutics
What
drug
fda
bio
new
roundup
approved
week
approval
big
class
companies
disease
drugs
known
make
medical
meeting
migraine
won
ahead
alzheimer’s
american
announced
annual
arguments
asco
ash
assessed
attention
biopharma
biotech
biotechs
blood
branded
cancer
choices
chose
close
commercialized
commissioner
Language
Current search:
fda
×
drugs
×
" indiana blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way